Multiple Myeloma Management in 2021
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview of Smoldering Multiple Myeloma By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 2: Role of Therapeutic Intervention in SMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 3: Approaching Early Treatment of High-Risk SMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 4: Individualized Induction Therapy for NDMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 5: ASH Updates on Transplant in NDMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 6: Future of MRD Assessment in NDMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 7: Approaching Treatment of RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 8: Role of IMiD-based Strategies for RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health EP. 9: Using PI-based Combinations in RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.
EP. 10: Emerging Novel Agents in RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM.
EP. 11: Targeting BCMA and CAR T Therapy in RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM.
EP. 12: Investigational BCMA Targets in RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM.
EP. 13: Non-BCMA Specific Targets in RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM.
EP. 14: Sequencing BCMA-Targeted Agents in RRMM By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM.
EP. 15: ASH Takeaways and Future Directions for Multiple Myeloma By Paul Richardson, MD, Dana-Farber Cancer Institute, Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center, David Siegel, MD, PhD, Hackensack Meridian Health, Saad Z. Usmani, MD, Atrium Health Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management.
